OXY-SENSE
"OXY-SENSE - A biosensor, image analysis, and work flow system platform for the study of neuronal injury and assessment of cellular bioenergetics"
| Coordinatore | ROYAL COLLEGE OF SURGEONS IN IRELAND
Organization address
address: Saint Stephen's Green 123 contact info |
| Nazionalità Coordinatore | Ireland [IE] |
| Totale costo | 579˙387 € |
| EC contributo | 579˙387 € |
| Programma | FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) |
| Code Call | FP7-PEOPLE-IAPP-2008 |
| Funding Scheme | MC-IAPP |
| Anno di inizio | 2009 |
| Periodo (anno-mese-giorno) | 2009-08-01 - 2013-07-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
ROYAL COLLEGE OF SURGEONS IN IRELAND
Organization address
address: Saint Stephen's Green 123 contact info |
IE (DUBLIN) | coordinator | 418˙860.00 |
| 2 |
LUXCEL BIOSCIENCES LTD
Organization address
address: BIOTRANSFER UNIT SUITE 3-32 BIOL contact info |
IE (CORK) | participant | 90˙916.00 |
| 3 |
SIEMENS AKTIENGESELLSCHAFT OESTERREICH
Organization address
address: SIEMENSSTRASSE 90 contact info |
AT (WIEN) | participant | 69˙611.00 |
| 4 |
LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
Organization address
address: GESCHWISTER SCHOLL PLATZ 1 contact info |
DE (MUENCHEN) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Cellular bioenergetics play a key role in the pathogenesis of acute and chronic neurological disorders. Novel sensors and analytical systems in combination with biomedical imaging can provide powerful new insights into the role of cellular bioenergetics in the propagation of disease states. OXY-SENSE is an Industry-Academia partnership of experienced neuroscientists, experts in optical oxygen sensing and probe design, plus a global player in biomedical imaging and software design. OXY-SENSE will develop and apply new technologies to investigate the role of cellular bioenergetics in neurological disorders and toxicity, with the aim to identify and validate new therapeutic targets and test systems. The partnership will allow for the development and dissemination of new, European born, technology by integrating the R&D activities of LUXCEL Biosciences, a SME and pioneer in oxygen sensing technologies, into a hypothesis-driven research programme. Expertise in image analysis, pathway modelling and software development resulting from a previous academia-industry partnership with SIEMENS will merge with the activities of OXY-SENSE. Through industrial and academic secondments, the recognised expertise of SIEMENS in software development and project management and the expertise of LUXCEL in sensor development will be mutually beneficial for all partners involved, and accelerate their discovery process and the commercialisation of these findings.'
Introduzione (Teaser)
A European consortium developed a novel oxygen sensor to evaluate the impact of cellular bioenergetics in the propagation of neurological disorders.
Descrizione progetto (Article)
A common feature of neurodegenerative disorders and ischaemic stroke is the apoptosis of neurons by yet unknown mechanisms. Overall, our understanding of the events that lead to neuronal injury after stroke is rather limited. Despite improvements in prevention and emergency treatments for stroke, current regimens are largely ineffective for addressing the cause of stroke.
Similarly, available treatments for neurodegenerative disorders target only disease symptoms and not the underlying causes. There is a great need for improved diagnosis at earlier time points considering the disability of patients suffering from stroke or neurodegenerative disorders.
To address this requirement, the EU-funded OXY-SENSE project proposed to develop a novel diagnostic oxygen sensor for evaluating mitochondrial function. Since oxygen is central in cellular bioenergetics, the concept behind this industry-academia alliance was to investigate its role in the pathogenesis of stroke and neurodegeneration.
Partners tested a number of sensors in confocal cell imaging approaches for in vitro cultures and in vivo imaging. Targeted oxygen-sensitive probes, image analysis software and systems modelling were among the project deliverables.
Most of the chemical compounds developed in the biotech and pharmaceutical industry fail to enter the clinical phase due to intrinsic toxicity. As a result, more integrated, effective test systems for drug toxicity analyses are required alongside new quality assurance guidelines. Project partners addressed the need of the pharmaceutical industry for toxicity screening.
The OXY-SENSE technology provides a diagnostic analyses platform for assessing mitochondrial dysfunction, cellular bioenergetics and drug toxicity. Implementation of this tool could bring new insight into the causes of neurodegenerative disorders and stroke with potential therapeutic implications.